Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 11Triple Negative Breast Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 2Meningeal Neoplasms 2Lymphoma, Non-Hodgkin 2HER2-positive Breast Cancer 2Stomach Neoplasms 1Rectal Neoplasms 1Pathologic Complete Response 1Meningeal Carcinomatosis 1Hemangiosarcoma 1Colorectal Neoplasms 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

Capecitabine 29Oxaliplatin 28Fluorouracil 16Radiotherapy 15Drug Therapy 11Leucovorin 10Bevacizumab 10Surgical Procedures, Operative 9Chemoradiotherapy 8Radiation 7sintilimab 6Consolidation Chemotherapy 6tislelizumab 5spartalizumab 5Specimen Handling 5Irinotecan 5Folfox protocol 5trifluridine tipiracil drug combination 4XELOX 4Neoadjuvant Therapy 4Endoscopy 4Cetuximab 4Biopsy 4toripalimab 3pembrolizumab 3irinotecan sucrosofate 3X-Rays 3Radiotherapy, Intensity-Modulated 3Proctectomy 3Mastectomy, Segmental 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Rectal Neoplasms × tucatinib × Clear all
NCT05672524 2026-05-12

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
37 enrolled
Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡